148 related articles for article (PubMed ID: 35669435)
1. Transcriptome Profiles Reveal a 12-Signature Metabolic Prediction Model and a Novel Role of Myo-Inositol Oxygenase in the Progression of Prostate Cancer.
Liu W; Xiang J; Wu X; Wei S; Huang H; Xiao Y; Zhai B; Wang T
Front Oncol; 2022; 12():899861. PubMed ID: 35669435
[TBL] [Abstract][Full Text] [Related]
2. The novel transcriptomic signature of angiogenesis predicts clinical outcome, tumor microenvironment and treatment response for prostate adenocarcinoma.
Gu CY; Dai B; Zhu Y; Lin GW; Wang HK; Ye DW; Qin XJ
Mol Med; 2022 Jul; 28(1):78. PubMed ID: 35836112
[TBL] [Abstract][Full Text] [Related]
3. Integrating single-cell and bulk RNA sequencing data unveils antigen presentation and process-related CAFS and establishes a predictive signature in prostate cancer.
Wang W; Li T; Xie Z; Zhao J; Zhang Y; Ruan Y; Han B
J Transl Med; 2024 Jan; 22(1):57. PubMed ID: 38221616
[TBL] [Abstract][Full Text] [Related]
4. Large-scale transcriptome profiles reveal robust 20-signatures metabolic prediction models and novel role of G6PC in clear cell renal cell carcinoma.
Xu WH; Xu Y; Tian X; Anwaier A; Liu WR; Wang J; Zhu WK; Cao DL; Wang HK; Shi GH; Qu YY; Zhang HL; Ye DW
J Cell Mol Med; 2020 Aug; 24(16):9012-9027. PubMed ID: 32567187
[TBL] [Abstract][Full Text] [Related]
5. Development of a novel five-gene immune-related risk model for the prognosis evaluation of prostate adenocarcinoma patients.
Fei H; Chen X
Am J Cancer Res; 2022; 12(5):2337-2349. PubMed ID: 35693084
[TBL] [Abstract][Full Text] [Related]
6. A N
Mei W; Jia X; Xin S; Liu X; Jin L; Sun X; Zhang JX; Zhang B; Yang G; Chen P; Ye L
J Oncol; 2022; 2022():8604216. PubMed ID: 35602299
[TBL] [Abstract][Full Text] [Related]
7. Immune infiltration phenotypes of prostate adenocarcinoma and their clinical implications.
Ma Z; Cheng X; Yue T; Shangguan X; Xin Z; Zhang W; Pan J; Wang Q; Xue W
Cancer Med; 2021 Aug; 10(15):5358-5374. PubMed ID: 34128342
[TBL] [Abstract][Full Text] [Related]
8. Identification of Prognostic Biomarkers Associated with Cancer Stem Cell Features in Prostate Adenocarcinoma.
Zhang D; Zhang M; Zhang Q; Zhao Z; Nie Y
Med Sci Monit; 2020 Jul; 26():e924543. PubMed ID: 32735556
[TBL] [Abstract][Full Text] [Related]
9. Computer classification and construction of a novel prognostic signature based on moonlighting genes in prostate cancer.
Mei W; Jin L; Zhang B; Sun X; Yang G; Li S; Ye L
Front Oncol; 2022; 12():982267. PubMed ID: 36276080
[TBL] [Abstract][Full Text] [Related]
10. Identification of Molecular Subtype and Prognostic Signature for Prostate Adenocarcinoma based on Neutrophil Extracellular Traps.
Zheng Y; Sun H; Yang S; Liu W; Jiang G
J Cancer; 2024; 15(9):2678-2690. PubMed ID: 38577608
[No Abstract] [Full Text] [Related]
11. The Prognostic Signature and Therapeutic Value of Phagocytic Regulatory Factors in Prostate Adenocarcinoma (PRAD).
Xin S; Sun X; Jin L; Li W; Liu X; Zhou L; Ye L
Front Genet; 2022; 13():877278. PubMed ID: 35706452
[TBL] [Abstract][Full Text] [Related]
12. High Expression of PDLIM2 Predicts a Poor Prognosis in Prostate Cancer and Is Correlated with Epithelial-Mesenchymal Transition and Immune Cell Infiltration.
Piao S; Zheng L; Zheng H; Zhou M; Feng Q; Zhou S; Ke M; Yang H; Wang X
J Immunol Res; 2022; 2022():2922832. PubMed ID: 35707002
[TBL] [Abstract][Full Text] [Related]
13. Database Mining of Genes of Prognostic Value for the Prostate Adenocarcinoma Microenvironment Using the Cancer Gene Atlas.
Zhao X; Hu D; Li J; Zhao G; Tang W; Cheng H
Biomed Res Int; 2020; 2020():5019793. PubMed ID: 32509861
[TBL] [Abstract][Full Text] [Related]
14. Novel immune-related signature for risk stratification and prognosis in prostatic adenocarcinoma.
Zhao HB; Zeng YR; Han ZD; Zhuo YJ; Liang YK; Hon CT; Wan S; Wu S; Dahl D; Zhong WD; Wu CL
Cancer Sci; 2021 Oct; 112(10):4365-4376. PubMed ID: 34252262
[TBL] [Abstract][Full Text] [Related]
15. Gene expression analysis reveals a 5-gene signature for progression-free survival in prostate cancer.
Mou Z; Spencer J; Knight B; John J; McCullagh P; McGrath JS; Harries LW
Front Oncol; 2022; 12():914078. PubMed ID: 36033512
[TBL] [Abstract][Full Text] [Related]
16. A Novel Overall Survival Prediction Signature Based on Comprehensive Research in Prostate Cancer Bone Metastases.
Hu K; Hu X; Duan Y; Li W; Qian J; Chen J
Front Med (Lausanne); 2022; 9():815541. PubMed ID: 35783639
[TBL] [Abstract][Full Text] [Related]
17. Long non-coding RNA profile study identifies an immune-related lncRNA prognostic signature for prostate adenocarcinoma.
Liang L; Xia W; Yao L; Wu Q; Hua L; Cheng G; Wang Z; Zhao R
Int Immunopharmacol; 2021 Dec; 101(Pt A):108267. PubMed ID: 34740081
[TBL] [Abstract][Full Text] [Related]
18. Nur77 Serves as a Potential Prognostic Biomarker That Correlates with Immune Infiltration and May Act as a Good Target for Prostate adenocarcinoma.
Hu QY; Liu J; Zhang XK; Yang WT; Tao YT; Chen C; Qian YH; Tang JS; Yao XS; Xu YH; Wang JH
Molecules; 2023 Jan; 28(3):. PubMed ID: 36770929
[TBL] [Abstract][Full Text] [Related]
19. Utilizing Ubiquitination Patterns to Predict Prostate Cancer Prognosis and Devise a Therapeutic Response.
Zhang X; Wang Y; Chang Y; Wang J; Yan S; Xiao Y; Guo T; Lou Y; Ma J; Xu W; Ren S
Arch Esp Urol; 2023 May; 76(3):215-231. PubMed ID: 37340527
[TBL] [Abstract][Full Text] [Related]
20. Molecular cloning of the myo-inositol oxygenase gene from the kidney of baboons.
González-Álvarez R; Pérez-Ibave DC; Garza-Rodríguez ML; Lugo-Trampe Á; Delgado-Enciso I; Tejero-Barrera ME; Martínez-De-Villarreal LE; Garza-Guajardo R; Sánchez-Chaparro MM; Ruiz-Ayma G; Barboza-Quintana O; Barrera-Saldaña HA; Rocha-Pizaña MDR; Rodríguez-Sánchez IP
Biomed Rep; 2017 Oct; 7(4):301-305. PubMed ID: 29085625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
